1:10 · Spanish audio
Plasmapheresis and longevity
A look at the apheresis circuit and procedure, explained by the medical team.
GEMMA Technology
The GEMMA device is the only therapeutic apheresis platform in Latin America developed and operated by the same medical organization that created it. Developed by Apheresis Technology, a company co-founded by NexusMed's Medical Director.
40–50 min
per session
~70 ml
extracorporeal vol.
850+
centers in the network
The device
A technology designed from clinical practice, not the other way around.
Conventional therapeutic apheresis requires large equipment, a central venous catheter, and sessions of 3 to 4 hours. GEMMA was designed to remove these limitations without compromising the clinical efficacy of the procedure.
The result is a compact system that operates with peripheral venous access, reduces extracorporeal volume to ~70 ml, and completes each session in 40 to 50 minutes. Every GEMMA unit is operated directly by the NexusMed medical team, with no technical-service intermediaries.
GEMMA in the medical team's words
Dr. Cristina Zumbana explains everything the GEMMA platform makes possible.
Modular platform · With audio
Hemofenix lineage
The device that preceded GEMMA.
Patient during a session with a Hemofenix device, the portable generation that preceded GEMMA. The photograph documents the procedure, not clinical outcomes.
From Hemofenix to GEMMA · Technical lineage
Two decades operating single-needle apheresis led to our own platform: optimized plasma exchange.
Plasma exchange · With audio
Clinical deployment
Apheresis in a real care setting.
Record of a portable device in a private room. This photograph documents the care setting, not the device model or clinical outcomes.
Clinical implementation · Boston
People, equipment and real clinical practice.
Professionals gathered beside a patient and an apheresis circuit during a clinical session in Boston.
40–50 min
Duration per session
Compared to 3–4 hours with conventional systems.
~70 ml
Extracorporeal volume
Compared to 400–500 ml with standard equipment.
Peripheral
Venous access
No central venous catheter in most indications.
550,000+
Procedures across the network
Data accumulated across more than 850 centers in a dozen countries.
GEMMA · in operation
Technical detail
Control panel and extracorporeal flow.
Every session monitors pressure, flow, and volume in real time. The operator — always a physician from our team — adjusts the parameters based on each patient's individual clinical response. No generic protocols.
Collected plasma
The material collected during apheresis.
The bag contains material collected during the procedure. Plasma appearance or color alone does not diagnose disease or demonstrate treatment efficacy.
Why it matters
Controlling the device changes the quality of the procedure.
No third-party dependence
Most apheresis centers depend on rented equipment or outside maintenance. When the equipment fails, treatment is delayed. NexusMed operates with its own technology: maintenance, calibration, and technical support are handled in-house.
Protocols refined with real data
The medical team that designed GEMMA is the same one that operates it in every session. That creates a unique clinical feedback loop: data from every procedure directly informs the device's development. Few institutions in the world have that level of integration.
Lower burden for the patient
40–50 minutes versus 3–4 hours. Peripheral access versus central catheter. Extracorporeal volume of ~70 ml versus 400–500 ml. Each of these factors reduces the physiological stress of the procedure and improves tolerance, especially in multi-session protocols.
Clinical advantages
What GEMMA changes in practice.
Feature
GEMMA
Conventional system
Session duration
GEMMA40–50 min
Conventional3–4 hours
Venous access
GEMMAPeripheral
ConventionalCentral catheter
Extracorporeal volume
GEMMA~70 ml
Conventional400–500 ml
Patient comfort
GEMMAHigh
ConventionalModerate
Operator control
GEMMANexusMed team
ConventionalOutside provider
Maintenance
GEMMAIn-house
ConventionalDependent on third parties
The company behind the device
Apheresis Technology · 850+ clinical centers.
GEMMA is developed by Apheresis Technology, a company founded by the same medical team that leads NexusMed. With an operational presence in more than 850 clinical centers across a dozen countries, Apheresis Technology combines technology development with clinical experience accumulated over more than two decades.
This integration between the device manufacturer and the clinical center that operates it is unusual in the medical field. It allows NexusMed to maintain direct control over the quality of every procedure, refine protocols using real clinical data, and offer a technical continuity that other centers cannot replicate.
850+
Clinical centers
Active network
10+
Countries
Operational presence
25+
Years of development
Accumulated experience
Hands-on training
Every circuit is prepared and reviewed as a team.
Professionals review the circuit setup together before each procedure, as part of clinical staff training.
Integration protocol
GEMMA within the clinical protocol.
Apheresis is not the only element of a NexusMed protocol. GEMMA is integrated into an individualized therapeutic plan that may include regenerative medicine, cell therapy, biomarker evaluation, and subsequent clinical follow-up.
Clinical note
GEMMA does not replace conventional medical treatments. Its clinical indication is determined in consultation with the specialist physician based on each patient's medical history, biomarkers, and therapeutic goals.
NexusMed archive
Clinical documentation
Practice, training and real care settings. These photographs document clinical context, not treatment outcomes.
1 / 6
Initial consultation
Is apheresis part of your protocol?
Only a clinical evaluation can determine that. The first step is a consultation with our Medical Director.
Book an evaluation